Michael Schenker

机构：Texas Oncology, University of Medicine and Pharmacy of Craiova, Institute of Oncology Prof. Dr. Ion Chiricuta, Oncolab (Romania), University of Craiova · ORCID：0000-0003-2645-6391

发表论文 285 篇 · 总被引 19358 次 · h-index 48

代表论文

• Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer (2026 · New England Journal of Medicine · 被引 8)
• Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial (2026 · The Lancet · 被引 2)
• Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): PD-L1 subgroup analysis from HERIZON-GEA-01. (2026 · Journal of Clinical Oncology · 被引 1)
• CheckMate-9DW 4-year follow-up: Overall survival by depth of response and outcomes in long-term survivors. (2026 · Journal of Clinical Oncology · 被引 1)
• Safety and efficacy of pegfilgastim for the prophylaxis of chemotherapy-induced neutropenia: A prospective, observational, multicenter, single-arm study (2026 · Research Square)
• Data from Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab–Based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer (2026)